Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05934149 · ClinicalTrials.gov registry record
Lupus Landmark Study: A Prospective Registry and Biorepository
A clinical trial of Lupus Nephritis and Systemic Lupus Erythematosus (SLE), sponsored by Lupus Research Alliance.
- Recruiting
- Registry status
- 3,500
- Enrollment target
- 20
- Study locations
NCT05934149: Recruiting study of Lupus Nephritis and Systemic Lupus Erythematosus (SLE), sponsored by Lupus Research Alliance.
NCT05934149 is a study of Lupus Nephritis and Systemic Lupus Erythematosus (SLE) that is actively recruiting participants, run by Lupus Research Alliance. The registered enrollment target is 3,500 participants, above the 194-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (1704% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05934149, a study of Lupus Nephritis and Systemic Lupus Erythematosus (SLE), is actively recruiting participants, sponsored by Lupus Research Alliance.
- RECRUITING
- Registry status
- 3,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).
Primary Outcome
Resource intended to be used to address research questions based upon three categorical time frames (historical, cross-sectional, and longitudinal) with specified scientific topics proposed upon request to access the resources.
Conditions Studied
Study Locations (20)
New York
- The Feinstein Institutes for Medical Research - Manhasset
- Columbia University Medical Center - New York
- Northwell Health - New York
- SUNY Upstate - Syracuse
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- University of Arizona - Tucson
California
- Wallace Rheumatic Studies Center - Beverly Hills
Florida
- University of Miami - Miami
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago - Chicago
Massachusetts
- University of Massachusetts Memorial Health - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2035-12 |
What NCT05934149 shows while recruiting
NCT05934149 is an observational study that tracks outcomes without assigning an intervention. Its 3,500 participants enrollment target places it among the larger protocols in the corpus, above the 194-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (1704% higher).
The record links to 3 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 0 interventions.
NCT05934149 names 20 study sites across 17 states, led by New York, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05934149 about?
NCT05934149 is a clinical study titled "Lupus Landmark Study: A Prospective Registry and Biorepository". The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).
What is the current status of trial NCT05934149?
This trial is currently recruiting. The enrollment target is 3,500 participants. The study started on 2023-06-28. Estimated completion is 2035-12.
What conditions does trial NCT05934149 study?
This clinical trial studies the following conditions: Lupus Nephritis, Systemic Lupus Erythematosus (SLE), Neuropsychiatric Systemic Lupus Erythematosus.
Who is sponsoring clinical trial NCT05934149?
This trial is sponsored by Lupus Research Alliance, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05934149 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05934149's enrollment target sits among peer trials
3,500 1st of 30 higher than 30 of 30 other Lupus Nephritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
-
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
RECRUITING · Phase 3
-
VIBRANT: VIB4920 for Active Lupus Nephritis
RECRUITING · Phase 2
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI